Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

Fig. 5

The frequency of irAEs according to the combination of CA19-9 and P-CRP Group A, both CA19-9Low and P-CRPLow; Group B, either CA19-9High or P-CRPHigh; Group C, both CA19-9High and P-CRPHigh; CA19-9, carbohydrate antigen 19–9; irAEs, immune-related adverse events; P-CRP, platelet count × serum C-reactive protein level multiplier value; ROC, receiver operating characteristic

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us